The results indicated that DCTN2 expression was dysregulated in most tumours, with elevated expression in many type of cancers, such as HCC, glioblastoma (GBM), pancreatic cancer and decreased expression in other cancers, such as breast cancer, colocteral cancer and ovarian cancer (Figure 1A). Here, DCTN2 is linked to pancreatic neoplasm.